San Francisco—Clinicians can minimize the potential for long-term cardiotoxic effects of cancer treatment by heeding some recommendations from the growing field of cardio-oncology.
Anthracycline-based chemotherapy regimens are among the most common cardiotoxicity culprits in this clinical setting, along with the monoclonal antibody trastuzumab (Herceptin, Genentech); both are mainstays of many current breast cancer systemic treatment regimens, noted Sandra Cuellar, PharmD, a clinical